Reported Earlier, Moderna's New COVID Vaccine Approved in Taiwan for Kids and Adults
Portfolio Pulse from Benzinga Newsdesk
Moderna's updated COVID-19 vaccine, Spikevax, has been approved by Taiwan's FDA for use in individuals six months and older. The vaccine targets the SARS-CoV-2 variant JN.1. Regulatory reviews are ongoing globally.
September 03, 2024 | 7:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's updated COVID-19 vaccine Spikevax has been approved in Taiwan, targeting the JN.1 variant. This approval could boost Moderna's market presence and sales, with further global regulatory decisions pending.
The approval of Moderna's updated vaccine in Taiwan is a significant regulatory milestone, potentially increasing sales and market presence. The ongoing global regulatory reviews could further enhance Moderna's position if approvals are granted.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90